OR WAIT null SECS
The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
July 23, 2024
Article
This supplemental new drug application for once-daily roflumilast foam follows positive results of the ARRECTOR phase 3 study.
These findings represent the first comprehensive research into the greater frequency of APS autoantibodies linked with treating psoriasis with TNF inhibitors.
July 22, 2024
In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.
These data suggest that the introduction of the concept of circadian syndrome contributes to greater understanding of risk management for those with psoriasis.
July 19, 2024
These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.
July 18, 2024
These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.
July 17, 2024
A study with real-world data showed certolizumab pegol was effective in treating psoriasis a year later, with a probability of 1-year persistence at approximately 85%.
July 16, 2024
Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.
In this analysis, investigators highlighted the results of treating psoriasis with deucravacitinib in the phase 3 POETYK PSO-1 and PSO-2 trials.
July 15, 2024
This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.